PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation

Bookmark and Share
Published: 28 Sep 2019
Views: 373
Rating:
Save
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

Prof Isabelle Ray-Coquard presents data from the PAOLA-1/ENGOT-ov25 trial during a press conference at the 2019 ESMO congress.

This was a phase III randomised trial which looked at the maintenance combined targeted therapy of PARP inhibitor olaparib added to bevacizumab, in patients with and without a BRCA mutation.